Helping gene therapy work better for CLN3 (juvenile Batten) by fixing brain circuit activity
Network modulation to improve gene therapy in CLN3 disease
This work looks at whether correcting abnormal brain network activity can help gene therapy better restore thinking, vision, and seizure control for children with CLN3 (juvenile Batten) disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11143157 on NIH RePORTER |
What this research studies
As someone affected by CLN3, this project studies disease-causing changes in brain circuits using mouse models that mimic the childhood vision loss, seizures, and dementia seen in patients. Researchers measure electrical brain activity with tools like EEG and voltage-sensitive dye imaging to find consistent problems in the hippocampus and related networks. They will test ways to modulate those networks alongside gene replacement so that restoring the missing protein also restores circuit function. The aim is to identify strategies that could be moved into human trials to improve symptoms that protein restoration alone has not fixed.
Who could benefit from this research
Good fit: Children and adolescents with genetically confirmed CLN3 (juvenile Batten) disease, especially those early in their disease course before severe neurologic loss, would be the most relevant candidates for future trials informed by this work.
Not a fit: People without CLN3 disease, and individuals whose brains already have severe, long-standing damage, are unlikely to benefit from these specific combined network-and-gene approaches.
Why it matters
Potential benefit: If successful, this approach could make gene therapies actually improve brain function and reduce vision loss, seizures, and cognitive decline in people with CLN3 disease.
How similar studies have performed: Previous brain-directed gene therapies have often restored missing proteins in the CNS but frequently did not improve clinical symptoms, so combining gene replacement with network-focused interventions is a newer strategy with limited prior success.
Where this research is happening
Philadelphia, United States
- Children's Hosp of Philadelphia — Philadelphia, United States (Active)
Researchers
- Principal investigator: Ahrens-Nicklas, Rebecca Clare — Children's Hosp of Philadelphia
- Study coordinator: Ahrens-Nicklas, Rebecca Clare
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.